Luqa Pharmaceuticals markets innovative solutions in dermatology and other specialty areas, focusing on medical, corrective and aesthetic product lines used mainly by physicians to enhance patients’ appearance. Led by CEO Robert Braithwaite, the company acquires, develops and commercializes healthcare products across medical and aesthetic categories. Founded in 2010, Luqa launched its first product in 2013 and has since released an additional eight products, with three more expected in 2015. The company intends to use new funding to expand, develop and fund ongoing operations and commercialization of its product range. The articles describe ongoing commercialization and product rollout as central to Luqa’s near-term plans. No revenue or user metrics were disclosed in the article.

Total raised

$15M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2015